PAVmed Plans Spin-Off And Marketing Push For Lucid Diagnostics
Lucid, which markets the EsoGuard test for Barrett’s esophagus, will become a separate public company, either through an IPO or a business combination with a health care SPAC.
You may also be interested in...
Guardant wants to become “one-stop-shop” in the cancer care continuum with the launch of an early-stage colorectal cancer test and planned launch of a tissue-based test.
As the SPAC boom continues, innovative medtechs are expected to become acquisition targets.
Inivata will remain a separate liquid biopsy division alongside NeoGenomics’ growing clinical, pharma and informatics divisions.